瑞替普酶治疗急性心肌梗死的临床效果观察

摘要

目的：观察急性心肌梗死经瑞替普酶治疗的临床效果。方法选取我院2012～2014年期间收治的64例心肌梗死患者并随机分为观察组与对照组（各32例），两组患者均在基础药物治疗的基础上分别给予瑞替普酶和尿激酶治疗。结果观察组血管再通率（93.7%）明显优于对照组（75.0%），两组间差异显著（P＜0.05），而观察组与对照组之间不良反应率无明显差异（P＞0.05）。结论瑞替普酶治疗急性心肌梗死效果显著。%ObjectiveTo observe clinical effect on reteplase for acute myocardial infarction.Methods 64 patients with myocardial infarction from 2012 to 2014 in our hospital were randomlyselected into observation group (n=32) and control group (n=32), patients of two groups were given reteplase and urokinase therapy on the basis of primary drug treatment. ResultsThe recanalization rate (93.7%) in the observation group was significantly better than the control group (75.0%) (P<0.05), there was no signiifcant difference of adverse reaction rate between thetwo groups (P>0.05).ConclusionThe clinical effect of reteplase for acute myocardial infarction is obvious.